Welcome to our dedicated page for Crispr Therapeut SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG (Nasdaq: CRSP) files detailed reports with the U.S. Securities and Exchange Commission that document its financial condition, clinical pipeline progress, collaborations, and capital markets activity. On this SEC filings page, Stock Titan aggregates CRSP’s regulatory documents and pairs them with AI-powered summaries to help readers interpret the implications of each filing.
For a gene editing biopharmaceutical company like CRISPR Therapeutics, annual reports on Form 10-K and quarterly reports on Form 10-Q typically describe the status of programs such as CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, in vivo liver editing candidates like CTX310 and CTX320, SyNTase-based CTX460 for alpha-1 antitrypsin deficiency, zugo-cel in autoimmune and oncology indications, and siRNA collaborations such as SRSD107/CTX611 with Sirius Therapeutics. These reports also outline risk factors, research and development priorities, and collaboration structures with partners including Vertex Pharmaceuticals.
Current reports on Form 8-K provide more focused updates on material events, such as quarterly financial results, business updates, and capital-raising actions. For example, recent 8-K filings describe the announcement of quarterly results and the use of an at-the-market equity program under an Open Market Sale Agreement with Jefferies to offer additional common shares under a shelf registration statement.
Investors can also use this page to monitor registration statements, prospectus supplements, and other offering-related filings that detail how CRISPR Therapeutics issues new equity, as well as any proxy materials that address governance and shareholder matters. Stock Titan’s tools surface new CRSP filings in near real time from EDGAR and apply AI-generated highlights so readers can quickly locate key disclosures on clinical data, collaboration terms, cash runway, and share issuance without reading every page.
CRISPR Therapeutics AG is soliciting shareholder votes at its 2026 Annual General Meeting to be held on June 4, 2026 in Zurich. The Board asks shareholders to approve the 2025 Swiss management report and financial statements and to carry forward a net loss of CHF 508,714,076.
The meeting agenda includes director and auditor re-elections, approval of director and executive compensation limits (separate binding votes), increases to the capital band and conditional share capital, and approval of a new 2026 Stock Option and Incentive Plan. Shareholders of record on April 20, 2026 may vote; the Board recommends "FOR" all proposals.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported a mix of equity grants, vesting, and a small share sale tied to taxes. He received a stock option for 38,499 Common Shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting on April 20, 2026. He was also granted 25,000 Restricted Stock Units (RSUs) that will vest in four annual installments of 6,250 shares each from March 20, 2027 through March 20, 2030.
On March 20, 2026, 6,250 RSUs from a prior 2024 grant vested and were converted into 6,250 Common Shares. On March 23, 2026, 3,182 Common Shares were sold at $46.78 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnote states was not a discretionary trade. After these transactions, Kasinger directly held 94,308 Common Shares, which remain subject to a lock-up agreement related to the company’s offering of convertible senior notes due 2031.
CRISPR Therapeutics CEO Samarth Kulkarni reported a mix of equity grants, vesting, and a small mandated share sale. On March 20, 2026, restricted stock units covering 19,687 Common Shares vested and were settled into shares, and he received a new stock option for 114,249 Common Shares at an exercise price of $46.24, plus a new restricted stock unit award for 81,875 Common Shares with vesting from 2027 through 2030.
On March 23, 2026, 10,020 Common Shares were sold at $46.78 per share solely to cover tax withholding tied to the RSU vesting, pursuant to the company’s RSU Settlement Policy and described as a non-discretionary transaction. After these events, Kulkarni held 255,501 Common Shares directly, and certain shares remain subject to a lock-up agreement related to the company’s convertible senior notes due 2031.
CRISPR Therapeutics AG Chief Financial Officer Prasad Raju reported a mix of equity awards, an option exercise, and a mandated share sale. On March 20, 2026, he received a stock option covering 38,499 Common Shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting April 20, 2026. He was also granted 27,500 restricted stock units (RSUs), scheduled to vest in four annual tranches from March 20, 2027 through March 20, 2030.
On the same date, 6,250 RSUs from a prior 2024 award vested and were converted into 6,250 Common Shares. On March 23, 2026, Raju sold 3,708 Common Shares at an average price of $46.78 per share. A footnote states this sale was required to cover tax withholding on the RSU vesting under the company’s RSU Settlement Policy and "does not represent a discretionary trade". After these transactions, he directly held 15,565 Common Shares, which remain subject to a lock-up agreement related to the issuer’s convertible senior notes due 2031.
CRISPR Therapeutics AG granted equity awards to its Chief Medical Officer, Naimish Patel. On March 20, 2026, he received stock options covering 38,499 common shares at an exercise price of $46.24 per share, vesting in 48 equal monthly installments starting April 20, 2026.
He was also awarded 30,000 restricted stock units, each representing one common share. These RSUs vest in four equal annual installments on March 20 of 2027, 2028, 2029 and 2030. Both awards are recorded as direct ownership and reflect compensation-related acquisitions rather than open-market purchases.
CRISPR Therapeutics AG Chief Medical Officer Naimish Patel reported routine equity compensation activity, including RSU vesting and a mandated tax-related sale. On March 14, 2026, 8,125 Restricted Stock Units converted into 8,125 Common Shares at $0.00 per share, representing the first quarter of a 32,500-share RSU grant awarded on March 14, 2025.
A separate footnote explains that 3,150 Common Shares were sold at $48.26 per share on March 16, 2026 solely to cover tax withholding obligations tied to this vesting, as required by the company’s RSU Settlement Policy, and that this did not represent a discretionary trade. Following these transactions, Patel directly owns 13,143 Common Shares, including 592 acquired under the 2016 Employee Stock Purchase Plan, and holds 24,375 unvested Restricted Stock Units that continue to vest annually through March 14, 2029.
CRISPR Therapeutics AG Chief Financial Officer Prasad Raju exercised and vested restricted stock units and related common shares, then disposed of a portion mainly for tax obligations and a gift. On March 14, 2026, he acquired 16,875 common shares through the conversion of restricted stock units granted in 2023 and 2025. On March 16, 2026, 9,869 common shares were sold at $48.26 per share to satisfy tax withholding requirements under the company’s RSU Settlement Policy, and 750 shares were transferred as a bona fide gift without consideration. After these transactions, he directly held 13,023 common shares, which remain subject to a lock-up related to the company’s convertible senior notes due 2031.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported RSU vesting and a related share sale. On March 14, 2026, 6,875 restricted stock units converted into 6,875 common shares at $0.00 per share, as part of a 27,500-share RSU grant vesting annually from 2026 to 2029.
On March 16, 2026, he sold 3,450 common shares at $48.26 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnote states was not a discretionary trade. After these transactions, he directly holds 91,240 common shares and 20,625 restricted stock units, with remaining shares subject to a lock-up agreement tied to the company’s convertible senior notes due 2031.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported RSU vesting and a related tax sale. On March 14, 2026, 20,625 Restricted Stock Units vested and were converted into 20,625 Common Shares at a conversion price of $0.00 per share.
The vested RSUs are part of an 82,500-share award granted on March 14, 2025, scheduled to vest in four equal annual installments through March 14, 2029. On March 16, 2026, 10,349 Common Shares were sold at $48.26 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnotes state does not represent a discretionary trade. After these transactions, Kulkarni directly holds 245,834 Common Shares and 61,875 Restricted Stock Units.
CRISPR Therapeutics completed a private offering of $600.0 million aggregate principal amount of convertible senior notes due 2031, generating approximately $585.2 million in net proceeds for general corporate purposes. The notes are senior unsecured obligations with an effective coupon of 1.125%, increased to 1.7308% to offset anticipated Swiss withholding tax.
Holders may convert at an initial rate of 13.0617 common shares per $1,000 principal amount, implying a conversion price of about $76.56 per share, a 45.0% premium to the $52.80 last reported sale price on the Nasdaq Global Market on March 10, 2026. Initially, a maximum of 11,363,580 common shares may be delivered upon conversion based on the initial maximum conversion rate.
The notes mature on March 1, 2031, pay interest semiannually starting September 1, 2026, and are redeemable at the company’s option on or after March 6, 2029 if share price conditions are met. They were sold in an unregistered Rule 144A private placement, and the shares issuable upon conversion are expected to be delivered in transactions exempt under Section 3(a)(9).